IMMX (STOCKS)
Immix Biopharma, Inc. Common Stock
$9.690000
+0.430000 (+4.64%)
Prev close: $9.260000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Ilya Rachman
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $511.11M
- Employees
- 21
- P/E (TTM)
- -10.88
- P/B (TTM)
- 5.23
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.28 | $-0.16 | -0.1209 | -75.99% |
|
Sep 2025 (Q3)
|
$-0.24 | $-0.19 | -0.0462 | -23.84% |
|
Jun 2025 (Q2)
|
$-0.22 | $-0.16 | -0.0568 | -34.80% |
|
Mar 2025 (Q1)
|
$-0.15 | $-0.23 | +0.0846 | +36.06% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $555.53K |
| Operating Expenses | $29.96M |
| Research and Development | $16.26M |
| Other Operating Expenses | $13.70M |
| Operating Income/Loss | -$29.96M |
| Income/Loss From Continuing Operations After Tax | -$29.44M |
| Income/Loss From Continuing Operations Before Tax | -$29.40M |
| Income Tax Expense/Benefit | $37.72K |
| Net Income/Loss | -$29.44M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$29.44M |
| Net Income/Loss Available To Common Stockholders, Basic | -$29.44M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.89 |
| Diluted Earnings Per Share | -$0.89 |
| Basic Average Shares | 32,965,706 |
| Diluted Average Shares | 32,965,706 |
| Assets | $104.84M |
| Current Assets | $101.24M |
| Cash | $100.40M |
| Other Current Assets | $837.76K |
| Noncurrent Assets | $3.60M |
| Fixed Assets | $2.52M |
| Other Non-current Assets | $1.08M |
| Liabilities | $11.04M |
| Current Liabilities | $10.11M |
| Accounts Payable | $5.44M |
| Wages | $942.16K |
| Other Current Liabilities | $3.73M |
| Noncurrent Liabilities | $933.63K |
| Equity | $93.80M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $93.80M |
| Liabilities And Equity | $104.84M |
| Net Cash Flow From Operating Activities | -$23.93M |
| Net Cash Flow From Operating Activities, Continuing | -$23.93M |
| Net Cash Flow From Investing Activities | -$7.21M |
| Net Cash Flow From Investing Activities, Continuing | -$7.21M |
| Net Cash Flow From Financing Activities | $107.39M |
| Net Cash Flow From Financing Activities, Continuing | $107.39M |
| Exchange Gains/Losses | $3.84K |
| Net Cash Flow | $76.25M |
| Net Cash Flow, Continuing | $76.24M |
| Comprehensive Income/Loss | -$29.38M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$29.38M |
| Other Comprehensive Income/Loss | $61.22K |
| Other Comprehensive Income/Loss Attributable To Parent | $61.22K |